Χώρα: Σιγκαπούρη
Γλώσσα: Αγγλικά
Πηγή: HSA (Health Sciences Authority)
BETAXOLOL HCl EQV BETAXOLOL
NOVARTIS (SINGAPORE) PTE LTD
S01ED02
0.25% w/v
SOLUTION
BETAXOLOL HCl EQV BETAXOLOL 0.25% w/v
OPHTHALMIC
Prescription Only
ALCON-COUVREUR NV
ACTIVE
1991-05-18
InDesign CS4 140 x 504 / 140 x 22 mm AANTAL KLEUREN : 1 WS 22-10-2013 SGP RECTO-verso Betoptic S 0,25% 5/10 ml 64095-1 BELGIUM V5 PMS ZWART À 100% 64095-1 1. NAME OF THE MEDICINAL PRODUCT BETOPTIC ® S 0.25%, Sterile Ophthalmic Suspension 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 1 ml of BETOPTIC ® S Suspension contains 2.5 mg betaxolol base (equivalent to 2.8 mg betaxolol hydrochloride) Preservative: 1 ml suspension contains 0.1 mg benzalkonium chloride For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM BETOPTIC ® S 0.25% Eye Drops, Suspension is formulated as a sterile, multiple-dose suspension for topical ophthalmic use. It is a white to off-white suspension. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS BETOPTIC ® S Suspension contains betaxolol hydrochloride, a cardioselective beta-adrenergic receptor blocking agent. BETOPTIC ® S Suspension has been shown to be effective in lowering intraocular pressure and may be used in patients with chronic open-angle glaucoma and ocular hypertension. It may be used alone or in combination with other intraocular pressure lowering medications. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION POSOLOGY Use in adults (including elderly) The recommended dose is one or two drops of BETOPTIC ® S Suspension in the affected eye(s) twice daily. In some patients, the intraocular pressure lowering responses to BETOPTIC ® S Suspension may require a few weeks to stabilize. As with any new medication, careful monitoring of patients is advised. If the intraocular pressure of the patient is not adequately controlled on this regimen, concomitant therapy with pilocarpine and other miotics, and/or epinephrine and/or carbonic anhydrase inhibitors can be instituted. Use in hepatic and renal impairment The safety and efficacy of BETOPTIC ® S Suspension in patients with hepatic and renal impairment have not been established. Use in children Safety and effectiveness in children have not be established. METHOD Διαβάστε το πλήρες έγγραφο
Betoptic S Oct2022.SIN Page 1 of 6 BETOPTIC® S 0.25% Eye Drops SUSPENSION (BETAXOLOL) 1. NAME OF THE MEDICINAL PRODUCT BETOPTIC®S 0.25 %, Eye Drops Suspension 2. QUALITATIVE AND QUANTITIVE COMPOSITION 1 ml of Suspension contains 2.5 mg betaxolol base (equivalent to 2.8 mg betaxolol hydrochloride) Preservative : 1 ml suspension contains 0.1 mg benzalkonium chloride Excipients: Mannitol, Poly(styrene-divinylbenzene) Sulfonic Acid, Carbomer 974P, Disodium Edetate, Benzalkonium chloride N-lauroylsarcosine, Boric Acid, Concentrated Hydrochloric Acid and/or Sodium Hydroxide (to adjust pH) and Purified Water 3. PHARMACEUTICAL FORM Eye Drops, Suspension white to off-white sterile suspension. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS BETOPTIC® S Suspension contains betaxolol, a cardioselective beta-adrenergic receptor blocking agent (beta-blocker). BETOPTIC® S Suspension is indicated for the reduction of elevated intraocular pressure in patients with chronic open-angle glaucoma or ocular hypertension. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION POSOLOGY Use in adults The recommended dose is 1 or 2 drops of BETOPTIC® S Suspension in the affected eye(s) twice daily. In some patients, the intraocular pressure lowering responses to BETOPTIC S Suspension may require a few weeks to stabilise. As with any new medication, careful monitoring of patients is advised. If the intraocular pressure of the patient is not adequately controlled on this regimen, concomitant therapy with other anti-glaucoma agents can be instituted. When a patient is transferred from a single anti-glaucoma agent, continue the agent already used and add 1 drop of BETOPTIC S suspension in the affected eye(s) twice a day. On the following day, discontinue the previous anti-glaucoma agent completely and continue with BETOPTIC S suspension. When a patient is transferred from several concomitantly administered anti-glaucoma agents, individualisation is required. Adjustment should involve 1 agent at a time made at intervals of not less than 1 week. Use Διαβάστε το πλήρες έγγραφο